Hyep Ivan 4

What Happened

• Hyep Ivan, Chief Financial Officer of Bicara Therapeutics (BCAX), was granted a derivative equity award covering 125,000 shares on February 2, 2026. The award is reported at $0.00 on the Form 4 (an equity grant/derivative acquisition), meaning no cash was paid by the reporting person at grant.

Key Details

• Transaction date: 2026-02-02; Form 4 filed: 2026-02-04 (timely — within the usual two-business-day window).
• Shares/units granted: 125,000 (derivative award). Reported price: $0.00.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnote: The award vests in 16 equal quarterly installments beginning Feb 2, 2026, subject to continued service (F1).
• No indication this was an exercise or sale — it is a grant/award for future vesting.

Context

• This was a compensation grant (derivative award) rather than an open-market purchase or sale. The award will vest over four years (16 quarters) if the CFO remains employed; there were no immediate share sales or cashless exercises reported. Grants are common for executive compensation and do not, by themselves, indicate immediate bullish or bearish trading intent.